Clinical Trial Update: The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection [Phase 4]

View source ↗

Summary

Phase 4 trial investigating peginterferon alfa-2a on recurrence-free survival in subjects with hepatic carcinoma after surgical resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Carcinoma
• Hepatitis B

Drugs mentioned

• Peginterferon alfa-2a (peginterferon alfa-2a)

Snippet

Sponsor: Huashan Hospital | Conditions: Chronic Hepatitis b, Hepatic Carcinoma | Phase 4 | Status: UNKNOWN